Israel Charo - Chemocentryx Senior Vice President - Research

CCXI -  USA Stock  

USD 15.32  0.21  1.39%

  President
Dr. Israel F. Charo, M.D., Ph.D., was appointed as Senior Vice President Research of ChemoCentryx, Inc. Prior to joining us, Dr. Charo was a ScientistinResidence at Bay City Capital since 2009. Dr. Charo has also served as a Senior Investigator at the Gladstone Institute of Cardiovascular Disease, and Professor of Medicine at University of California, San Francisco since 1991. He studies the role of chemokines in leukocyte trafficking and inflammation. His group cloned the chemokine receptor known as CCR2, and showed that it is a major driver for the recruitment of monocytemacrophages to developing atherosclerotic lesions. Prior to that, Dr. Charo was one of the founding scientists of COR Therapeutics, Inc. from 1988 until 1991, where he was part of the team that developed the platelet inhibitor Integrilin. Dr. Charo received his M.D. and Ph.D. from State University of New York Downstate, and is trained in internal medicine at The New York Hospital, Weill Medical Center and Rheumatology at UCSF
Age: 64        
650 210-2910  www.chemocentryx.com
Charo received his B.S. and M.S. in Engineering and Materials Science from SUNY Stony Brook, New York and University of California, Berkeley, respectively.

Chemocentryx Management Efficiency

Chemocentryx has return on total asset (ROA) of (11.2) % which means that it has lost $11.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (30.1) %, meaning that it created substantial loss on money invested by shareholders. Chemocentryx management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -24.01. The current Return on Average Assets is estimated to decrease to -0.13. Chemocentryx Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 77.33 Million. The current Revenue to Assets is estimated to increase to 0.18, while Return on Average Assets are projected to decrease to (0.13) .
The company currently holds 70.03 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Chemocentryx has a current ratio of 7.0, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 4 records

PRESIDENT Since

Robert JanssenDynavax Technologies
2018
David JohnsonDynavax Technologies
2014
Ryan SpencerDynavax Technologies
2019
Michael OstrachDynavax Technologies
2016
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. Chemocentryx (CCXI) is traded on NASDAQ Exchange in USA. It is located in 835 Industrial Road, San Carlos, CA 94070, United States and employs 133 people. Chemocentryx is listed under Pharmaceutical Products category by Fama And French industry classification.

Chemocentryx Leadership Team

Elected by the shareholders, the Chemocentryx's board of directors comprises two types of representatives: Chemocentryx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemocentryx. The board's role is to monitor Chemocentryx's management team and ensure that shareholders' interests are well served. Chemocentryx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemocentryx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Israel Charo, Senior Vice President - Research
Jan Hillson, Senior Vice President - Drug Development
Geoffrey Parker, Independent Director
Susan Kanaya, CFO, Sr. VP of Fin. and Secretary
Petrus Bekker, Senior Vice President - Clinical and Medical Affairs
Joseph Feczko, Independent Director
Markus Cappel, Chief Bus. Officer and Treasurer
William Fairey, COO, Executive Vice President
Thomas Edwards, Independent Director
James Tyree, Independent Director
Henry McKinnell, Director
Rajinder Singh, Senior Vice President - Research
Roger Lucas, Lead Independent Director
Rita Jain, Independent Director
Thomas Schall, Founder, Chairman, CEO and Pres

Chemocentryx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemocentryx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Chemocentryx Investors Sentiment

The influence of Chemocentryx's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Chemocentryx. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - CCXI

Chemocentryx Investor Sentiment

Most of Macroaxis users are currently bullish on Chemocentryx. What is your opinion about investing in Chemocentryx? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Trading with Chemocentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemocentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemocentryx will appreciate offsetting losses from the drop in the long position's value.

Chemocentryx Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Chemocentryx and Edesa Biotech. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.